Series A funding for protein degrader
A UK company with technology for potentially removing disease-associated proteins from the brain has raised $60 million in Series A financing from a syndicate led by 4BIO Capital and new investor Eli Lilly and Co. Oyster Therapeutics Ltd, formerly known as Kesmalea Therapeutics, has developed a new version of protein degradation, a natural process by which cells in the body breakdown proteins that are damaged or that are no longer needed in order to maintain equilibrium. As therapies, protein degraders are being used by multiple companies to clear defective proteins from cells.
